Le WD. Inauguration of a unique journal Ageing and Neurodegenerative Diseases: A new beginning seeking cures for age-related neurodegenerative diseases. Ageing Neurodegener Dis 2021, https://doi.org/10.20517/and.2021.01.
DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 2019, 14: 32.
Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 2013, 80: 1778–1783.
Hauser PS, Narayanaswami V, Ryan RO. Apolipoprotein E: From lipid transport to neurobiology. Prog Lipid Res 2011, 50: 62–74.
Li ZH, Shue F, Zhao N, Shinohara M, Bu GJ. APOE2: Protective mechanism and therapeutic implications for Alzheimer’s disease. Mol Neurodegener 2020, 15: 63.
Najm R, Jones EA, Huang YD. Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease. Mol Neurodegener 2019, 14: 24.
Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer’s disease: Progress to date and the path forward. Neuron 2019, 101: 820–838.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278: 1349–1356.
Rahman MM, Lendel C. Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology. Mol Neurodegener 2021, 16: 59.
Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2000, 97: 2892–2897.
Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010, 67: 122–131.
Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer’s disease: Allelic variation and receptor interactions. Neuron 1993, 11: 575–580.
Cho HS, Hyman BT, Greenberg SM, Rebeck GW. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 2001, 60: 342–349.
Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C. The binding of apolipoprotein E to oligomers and fibrils of amyloid-β alters the kinetics of amyloid aggregation. Biochemistry 2014, 53: 6323–6331.
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 2011, 3: 89ra57.
Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci 2012, 32: 15181–15192.
Ma QY, Zhao Z, Sagare AP, Wu YX, Wang M, Owens NC, et al. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Mol Neurodegener 2018, 13: 57.
Zhao N, Ren YX, Yamazaki Y, Qiao WH, Li FY, Felton LM, et al. Alzheimer’s risk factors age, APOE genotype, and sex drive distinct molecular pathways. Neuron 2020, 106: 727-742.e6.
Berger M, Cooter M, Roesler AS, Chung S, Park J, Modliszewski JL, et al. APOE4 copy number-dependent proteomic changes in the cerebrospinal fluid. J Alzheimers Dis 2021, 79: 511–530.
Main BS, Villapol S, Sloley SS, Barton DJ, Parsadanian M, Agbaegbu C, et al. Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury. Mol Neurodegener 2018, 13: 17.
Wang SW, Li BY, Solomon V, Fonteh A, Rapoport SI, Bennett DA, et al. Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4. Mol Neurodegener 2021, 16: 26.
Liu TF, Zhu B, Liu Y, Zhang XM, Yin J, Li XG, et al. Multi-omic comparison of Alzheimer’s variants in human ESC-derived microglia reveals convergence at APOE. J Exp Med 2020, 217: e20200474.
Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu ZH, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485: 512–516.
Liu YH, Jiao SS, Wang YR, Bu XL, Yao XQ, Xiang Y, et al. Associations between ApoEε4 carrier status and serum BDNF levels—new insights into the molecular mechanism of ApoEε4 actions in Alzheimer’s disease. Mol Neurobiol 2015, 51: 1271–1277.
Theendakara V, Patent A, Peters Libeu CA, Philpot B, Flores S, Descamps O, et al. Neuroprotective Sirtuin ratio reversed by ApoE4. Proc Natl Acad Sci U S A 2013, 110: 18303–18308.
Farmer BC, Williams HC, Devanney NA, Piron MA, Nation GK, Carter DJ, et al. APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis. Mol Neurodegener 2021, 16: 1–18.
Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world Is APOE*4 a ‘thrifty’ allele? Ann Hum Genet 1999, 63: 301–310.
Tan L, Yu JT, Zhang W, Wu ZC, Zhang Q, Liu QY, et al. Association of GWAS-linked loci with late-onset Alzheimer’s disease in a northern Han Chinese population. Alzheimers Dement 2013, 9: 546–553.
Agarwal R, Tripathi CB. Association of apolipoprotein E genetic variation in Alzheimer’s disease in Indian population: A meta-analysis. Am J Alzheimers Dis Other Demen 2014, 29: 575–582.
Quiroga P, Calvo C, Albala C, Urquidi J, Santos JL, Pérez H, et al. Apolipoprotein E polymorphism in elderly Chilean people with Alzheimer’s disease. Neuroepidemiology 1999, 18: 48–52.
Abyadeh M, Djafarian K, Heydarinejad F, Alizadeh S, Shab-Bidar S. Association between apolipoprotein E gene polymorphism and Alzheimer’s disease in an Iranian population: A meta-analysis. J Mol Neurosci 2019, 69: 557–562.
Tang MX, Cross P, Andrews H, Jacobs DM, Small S, Bell K, et al. Incidence of AD in African-Americans, Caribbean hispanics, and caucasians in northern Manhattan. Neurology 2001, 56: 49–56.
Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement 2016, 12: 216–224.
Matthews KA, Xu W, Gaglioti AH, Holt JB, Croft JB, Mack D, et al. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged ≥65 years. Alzheimers Dement 2019, 15: 17–24.
Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, et al. Incidence of Alzheimer disease in a biracial urban community: Relation to apolipoprotein E allele status. Arch Neurol 2003, 60: 185–189.
Blue EE, Horimoto ARVR, Mukherjee S, Wijsman EM, Thornton TA. Local ancestry at APOE modifies Alzheimer’s disease risk in Caribbean Hispanics. Alzheimers Dement 2019, 15: 1524–1532.
Rajabli F, Feliciano BE, Celis K, Hamilton-Nelson KL, Whitehead PL, Adams LD, et al. Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations. PLoS Genet 2018, 14: e1007791. https://doi.org/10.1371/journal.pgen.1007791.
Marca-Ysabel MV, Rajabli F, Cornejo-Olivas M, Whitehead PG, Hofmann NK, Illanes Manrique MZ, et al. Dissecting the role of Amerindian genetic ancestry and the ApoE ε4 allele on Alzheimer disease in an admixed Peruvian population. Neurobiol Aging 2021, 101: 298–315.
Farrer LA, Friedland RP, Bowirrat A, Waraska K, Korczyn A, Baldwin CT. Genetic and environmental epidemiology of Alzheimer’s disease in arabs residing in Israel. J Mol Neurosci 2003, 20: 207–212.
Lai E, Riley J, Purvis I, Roses A. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics 1998, 54: 31–38.
Martin ER, Lai EH, Gilbert JR, Rogala AR, Afshari AJ, Riley J, et al. SNPing away at complex diseases: Analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet 2000, 67: 383–394.
Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer’s disease. Pharmacogenomics J 2010, 10: 375–384.
Crenshaw DG, Gottschalk WK, Lutz MW, Grossman I, Saunders AM, Burke JR, et al. Using genetics to enable studies on the prevention of Alzheimer’s disease. Clin Pharmacol Ther 2013, 93: 177–185.
Caselli RJ, Dueck AC, Huentelman MJ, Lutz MW, Saunders AM, Reiman EM, et al. Longitudinal modeling of cognitive aging and the TOMM40 effect. Alzheimers Dement 2012, 8: 490–495.
Zhou XP, Chen Y, Mok KY, Kwok TCY, Mok VCT, Guo QH, et al. Non-coding variability at the APOE locus contributes to the Alzheimer’s risk. Nat Commun 2019, 10: 3310.
Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer’s disease: Assessing sex and gender differences. Clin Epidemiol 2014, 6: 37–48.
Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B. Very old women at highest risk of dementia and Alzheimer’s disease: Incidence data from the Kungsholmen Project, Stockholm. Neurology 1997, 48: 132–138.
Ott A, Breteler MM, van Harskamp F, Stijnen T, Hofman A. Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 1998, 147: 574–580.
Letenneur L, Gilleron V, Commenges D, Helmer C, Orgogozo JM, Dartigues JF. Are sex and educational level independent predictors of dementia and Alzheimer’s disease? Incidence data from the PAQUID project. J Neurol Neurosurg Psychiatry 1999, 66: 177–183.
Ganguli M, Dodge HH, Chen P, Belle S, DeKosky ST. Ten-year incidence of dementia in a rural elderly US community population: The MoVIES Project. Neurology 2000, 54: 1109–1116.
Kawas C, Gray S, Brookmeyer R, Fozard J, Zonderman A. Age-specific incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of Aging. Neurology 2000, 54: 2072–2077.
Bachman DL, Wolf PA, Linn RT, Knoefel JE, Cobb JL, Belanger AJ, et al. Incidence of dementia and probable Alzheimer’s disease in a general population: The Framingham Study. Neurology 1993, 43: 515–519.
Payami H, Montee KR, Kaye JA, Bird TD, Yu CE, Wijsman EM, et al. Alzheimer’s disease, apolipoprotein E4, and gender. JAMA 1994, 271: 1316–1317.
Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD, et al. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord 1999, 13: 216–221.
Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology 1999, 53: 321–331.
Altmann A, Tian L, Henderson VW, Greicius MD. Alzheimer’s Disease Neuroimaging Initiative Investigators. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann Neurol 2014, 75: 563–573.
Barrera J, Song LY, Gamache JE, Garrett ME, Safi A, Yun Y, et al. Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains. Mol Neurodegener 2021, 16: 58.
Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, et al. Gender modulates the APOE ε4 effect in healthy older adults: Convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci 2012, 32: 8254–8262.
Hohman TJ, Dumitrescu L, Barnes LL, Thambisetty M, Beecham G, Kunkle B, et al. Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurol 2018, 75: 989–998.
Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, et al. Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol 2019, 76: 542–551.
Rippon GA, Tang MX, Lee JH, Lantigua R, Medrano M, Mayeux R. Familial Alzheimer disease in Latinos: Interaction between APOE, stroke, and estrogen replacement. Neurology 2006, 66: 35–40.
Kang JH, Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol Aging 2012, 33: 1129–1137.
Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Hajian H, Finch CE. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol 1997, 143: 313–318.
Wang JM, Irwin RW, Brinton RD. Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in Hippocampus in vitro and in vivo. Proc Natl Acad Sci USA 2006, 103: 16983–16988.
Nathan BP, Barsukova AG, Shen F, McAsey M, Struble RG. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology 2004, 145: 3065–3073.
Brown CM, Choi E, Xu Q, Vitek MP, Colton CA. The APOE4 genotype alters the response of microglia and macrophages to 17beta-estradiol. Neurobiol Aging 2008, 29: 1783–1794.
Larramona-Arcas R, González-Arias C, Perea G, Gutiérrez A, Vitorica J, García-Barrera T, et al. Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice. Mol Neurodegener 2020, 15: 35.
Maldonado Weng J, Parikh I, Naqib A, York J, Green SJ, Estus S, et al. Synergistic effects of APOE and sex on the gut microbiome of young EFAD transgenic mice. Mol Neurodegener 2019, 14: 47.
Hebert LE, Scherr PA, Beckett LA, Albert MS, Pilgrim DM, Chown MJ, et al. Age-specific incidence of Alzheimer’s disease in a community population. JAMA 1995, 273: 1354–1359.
Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med 2009, 361: 255–263.
Williams OA, An Y, Armstrong N, Shafer AT, Helphrey J, Kitner-Triolo M, et al. O4–05-01: Apolipoprotein ε4 allele effects on longitudinal cognitive trajectories are sex- and age-dependent. Alzheimer’s Dement 2019, 15: P1241–P1242.
Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Med 2017, 14: e1002254. https://doi.org/10.1371/journal.pmed.1002254.
Bonham LW, Geier EG, Fan CC, Leong JK, Besser L, Kukull WA, et al. Age-dependent effects of APOE ε4 in preclinical Alzheimer’s disease. Ann Clin Transl Neurol 2016, 3: 668–677.
Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009, 72: 1487–1494.
Quevenco FC, van Bergen JM, Treyer V, Studer ST, Kagerer SM, Meyer R, et al. Functional brain network connectivity patterns associated with normal cognition at old-age, local β-amyloid, tau, and APOE4. Front Aging Neurosci 2020, 12: 46.
Wennberg AM, Tosakulwong N, Lesnick TG, Murray ME, Whitwell JL, Liesinger AM, et al. Association of apolipoprotein E ε4 with transactive response DNA-binding protein 43. JAMA Neurol 2018, 75: 1347–1354.
Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012, 79: 1645–1652.
Qin B, Xun P, Jacobs DR, Zhu N, Daviglus ML, Reis JP, et al. Intake of niacin, folate, vitamin B-6, and vitamin B-12 through young adulthood and cognitive function in midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Clin Nutr 2017, 106: 1032–1040.
Lefèvre-Arbogast S, Féart C, Dartigues JF, Helmer C, Letenneur L, Samieri C. Dietary B vitamins and a 10-year risk of dementia in older persons. Nutrients 2016, 8: E761.
Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. Lancet 2007, 369: 208–216.
Jayedi A, Rashidy-Pour A, Shab-Bidar S. Vitamin D status and risk of dementia and Alzheimer’s disease: A meta-analysis of dose-response. Nutr Neurosci 2019, 22: 750–759.
Zhao C, Tsapanou A, Manly J, Schupf N, Brickman AM, Gu Y. Vitamin D intake is associated with dementia risk in the Washington Heights-Inwood Columbia Aging Project (WHICAP). Alzheimers Dement 2020, 16: 1393–1401.
Zhang Y, Chen JN, Qiu JN, Li YJ, Wang JB, Jiao JJ. Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: A dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr 2016, 103: 330–340.
Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 2010, 6: 456–464.
Scarmeas N, Anastasiou CA, Yannakoulia M. Nutrition and prevention of cognitive impairment. Lancet Neurol 2018, 17: 1006–1015.
Wu L, Sun D. Adherence to Mediterranean diet and risk of developing cognitive disorders: An updated systematic review and meta-analysis of prospective cohort studies. Sci Rep 2017, 7: 41317.
Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de la Torre R, Martínez-González MÁ, et al. Mediterranean diet and age-related cognitive decline: A randomized clinical trial. JAMA Intern Med 2015, 175: 1094–1103.
Martínez-Lapiscina EH, Clavero P, Toledo E, Estruch R, Salas-Salvadó J, San Julián B, et al. Mediterranean diet improves cognition: The PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry 2013, 84: 1318–1325.
Morris MC, Tangney CC, Wang YM, Sacks FM, Bennett DA, Aggarwal NT. MIND diet associated with reduced incidence of Alzheimer’s disease. Alzheimers Dement 2015, 11: 1007–1014.
Hosking DE, Eramudugolla R, Cherbuin N, Anstey KJ. MIND not Mediterranean diet related to 12-year incidence of cognitive impairment in an Australian longitudinal cohort study. Alzheimers Dement 2019, 15: 581–589.
Fortier M, Castellano CA, Croteau E, Langlois F, Bocti C, St-Pierre V, et al. A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement 2019, 15: 625–634.
Neth BJ, Mintz A, Whitlow C, Jung Y, Solingapuram Sai K, Register TC, et al. Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer’s disease: A pilot study. Neurobiol Aging 2020, 86: 54–63.
Maddock J, Cavadino A, Power C, Hyppönen E. 25-hydroxyvitamin D, APOE ɛ4 genotype and cognitive function: findings from the 1958 British birth cohort. Eur J Clin Nutr 2015, 69: 505–508.
Feng L, Li JL, Yap KB, Kua EH, Ng TP. Vitamin B-12, apolipoprotein E genotype, and cognitive performance in community-living older adults: Evidence of a gene-micronutrient interaction. Am J Clin Nutr 2009, 89: 1263–1268.
Dursun E, Alaylıoğlu M, Bilgiç B, Hanağası H, Lohmann E, Atasoy IL, et al. Vitamin D deficiency might pose a greater risk for ApoEɛ4 non-carrier Alzheimer’s disease patients. Neurol Sci 2016, 37: 1633–1643.
van de Rest O, Wang YM, Barnes LL, Tangney C, Bennett DA, Morris MC. APOE ε4 and the associations of seafood and long-chain Omega-3 fatty acids with cognitive decline. Neurology 2016, 86: 2063–2070.
Morris MC, Brockman J, Schneider JA, Wang Y, Bennett DA, Tangney CC, et al. Association of seafood consumption, brain mercury level, and APOE ε4 status with brain neuropathology in older adults. JAMA 2016, 315: 489–497.
Stonehouse W, Conlon CA, Podd J, Hill SR, Minihane AM, Haskell C, et al. DHA supplementation improved both memory and reaction time in healthy young adults: A randomized controlled trial. Am J Clin Nutr 2013, 97: 1134–1143.
Gentreau M, Chuy V, Féart C, Samieri C, Ritchie K, Raymond M, et al. Refined carbohydrate-rich diet is associated with long-term risk of dementia and Alzheimer’s disease in apolipoprotein E ε4 allele carriers. Alzheimers Dement 2020, 16: 1043–1053.
van Lent DM, O’Donnell A, Beiser AS, Vasan RS, DeCarli CS, Scarmeas N, et al. Mind diet adherence and cognitive performance in the Framingham heart study. J Alzheimer’s Dis 2021, 82: 827–839.
Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: Randomized clinical trial. JAMA Neurol 2013, 70: 972–980.
Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, et al. Association of docosahexaenoic acid supplementation with alzheimer disease stage in apolipoprotein E ε4 carriers: A review. JAMA Neurol 2017, 74: 339–347.
Chouinard-Watkins R, Rioux-Perreault C, Fortier M, Tremblay-Mercier J, Zhang Y, Lawrence P, et al. Disturbance in uniformly 13C-labelled DHA metabolism in elderly human subjects carrying the apoE ε4 allele. Br J Nutr 2013, 110: 1751–1759.
Calder PC. Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochem Soc Trans 2017, 45: 1105–1115.
Fourrier C, Remus-Borel J, Greenhalgh AD, Guichardant M, Bernoud-Hubac N, Lagarde M, et al. Docosahexaenoic acid-containing choline phospholipid modulates LPS-induced neuroinflammation in vivo and in microglia in vitro. J Neuroinflammation 2017, 14: 170.
Bos MM, Noordam R, Blauw GJ, Slagboom PE, Rensen PCN, van Heemst D. The ApoE ε4 isoform: Can the risk of diseases be reduced by environmental factors? J Gerontol: Ser A 2019, 74: 99–107.
Zhao N, Liu CC, van Ingelgom AJ, Martens YA, Linares C, Knight JA, et al. Apolipoprotein E4 impairs neuronal insulin signaling by trapping insulin receptor in the endosomes. Neuron 2017, 96: 115-129.e5.
Li YM, Dickson DW. Enhanced binding of advanced glycation endproducts (AGE) by the ApoE4 isoform links the mechanism of plaque deposition in Alzheimer’s disease. Neurosci Lett 1997, 226: 155–158.
Hill CM, Dimitriou D, Baya WR, Gavlak-Dingle J, Lesperance V, et al. Cognitive performance in high-altitude Andean residents compared with low-altitude populations: From childhood to older age. Neuropsychology 2014, 28: 752–760.
Hota SK, Sharma VK, Hota K, Das S, Dhar P, Mahapatra BB, et al. Multi-domain cognitive screening test for neuropsychological assessment for cognitive decline in acclimatized lowlanders staying at high altitude. Indian J Med Res 2012, 136: 411–420.
Thielke S, Slatore CG, Banks WA. Association between alzheimer dementia mortality rate and altitude in California counties. JAMA Psychiatry 2015, 72: 1253–1254.
Russ TC, Murianni L, Icaza G, Slachevsky A, Starr JM. Geographical variation in dementia mortality in Italy, new Zealand, and Chile: The impact of latitude, vitamin D, and air pollution. Dement Geriatr Cogn Disord 2016, 42: 31–41.
Egert S, Rimbach G, Huebbe P. ApoE genotype: From geographic distribution to function and responsiveness to dietary factors. Proc Nutr Soc 2012, 71: 410–424.
Hu P, Qin YH, Jing CX, Lu L, Hu B, Du PF. Does the geographical gradient of ApoE4 allele exist in China? A systemic comparison among multiple Chinese populations. Mol Biol Rep 2011, 38: 489–494.
Huebbe P, Nebel A, Siegert S, Moehring J, Boesch-Saadatmandi C, Most E, et al. APOE ε4 is associated with higher vitamin D levels in targeted replacement mice and humans. FASEB J 2011, 25: 3262–3270.
Eisenberg DT, Kuzawa CW, Hayes MG. Worldwide allele frequencies of the human apolipoprotein E gene: Climate, local adaptations, and evolutionary history. Am J Phys Anthropol 2010, 143: 100–111.
Kaushal N, Ramesh V, Gozal D. Human apolipoprotein E4 targeted replacement in mice reveals increased susceptibility to sleep disruption and intermittent hypoxia. Am J Physiol Regul Integr Comp Physiol 2012, 303: R19–R29.
Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 335: 1503–1506.
Sawmiller D, Habib A, Hou HY, Mori T, Fan AR, Tian J, et al. A novel apolipoprotein E antagonist functionally blocks apolipoprotein E interaction with N-terminal amyloid precursor protein, reduces β-amyloid-associated pathology, and improves cognition. Biol Psychiatry 2019, 86: 208–220.
Wang LK, Hou HY, Zi D, Habib A, Tan J, Sawmiller D. Novel apoE receptor mimetics reduce LPS-induced microglial inflammation. Am J Transl Res 2019, 11: 5076–5085.
Ebenau JL, van der Lee SJ, Hulsman M, Tesi N, Jansen IE, Verberk IMW, et al. Risk of dementia in APOE ε4 carriers is mitigated by a polygenic risk score. Alzheimers Dement (Amst) 2021, 13: e12229. https://doi.org/10.1002/dad2.12229.
Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu GJ. Apolipoprotein E and Alzheimer disease: Pathobiology and targeting strategies. Nat Rev Neurol 2019, 15: 501–518.